BR112020021255A2 - formulações tamponadas de bevacizumabe para uso no tratamento de doenças - Google Patents

formulações tamponadas de bevacizumabe para uso no tratamento de doenças Download PDF

Info

Publication number
BR112020021255A2
BR112020021255A2 BR112020021255-5A BR112020021255A BR112020021255A2 BR 112020021255 A2 BR112020021255 A2 BR 112020021255A2 BR 112020021255 A BR112020021255 A BR 112020021255A BR 112020021255 A2 BR112020021255 A2 BR 112020021255A2
Authority
BR
Brazil
Prior art keywords
formulation
antibody
use according
respects
fact
Prior art date
Application number
BR112020021255-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Chris YONAN
Wiphusanee DENDAMRONGVIT
Martha Healy-Fried
Original Assignee
Outlook Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Outlook Therapeutics, Inc. filed Critical Outlook Therapeutics, Inc.
Publication of BR112020021255A2 publication Critical patent/BR112020021255A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112020021255-5A 2018-04-17 2019-04-17 formulações tamponadas de bevacizumabe para uso no tratamento de doenças BR112020021255A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658772P 2018-04-17 2018-04-17
US62/658,772 2018-04-17
US201862776686P 2018-12-07 2018-12-07
US62/776,686 2018-12-07
PCT/US2019/027790 WO2019204380A1 (en) 2018-04-17 2019-04-17 Buffered formulations of bevacizumab for use of treating diseases

Publications (1)

Publication Number Publication Date
BR112020021255A2 true BR112020021255A2 (pt) 2021-02-02

Family

ID=66429576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021255-5A BR112020021255A2 (pt) 2018-04-17 2019-04-17 formulações tamponadas de bevacizumabe para uso no tratamento de doenças

Country Status (12)

Country Link
US (1) US20210230261A1 (enExample)
EP (1) EP3781199A1 (enExample)
JP (1) JP2021522180A (enExample)
KR (1) KR20210011923A (enExample)
CN (1) CN112543645A (enExample)
AU (1) AU2019256289A1 (enExample)
BR (1) BR112020021255A2 (enExample)
CA (1) CA3097123A1 (enExample)
IL (1) IL278041A (enExample)
MX (1) MX2020010968A (enExample)
SG (1) SG11202010178XA (enExample)
WO (1) WO2019204380A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7713950B2 (ja) * 2020-03-04 2025-07-28 上海復宏漢霖生物技術股▲フン▼有限公司 ベバシズマブを含む薬物製剤
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2012019136A2 (en) * 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
CN106924184B (zh) * 2017-03-29 2020-07-17 烟台大学 一种眼部玻璃体注射用多囊脂质体及其制备方法

Also Published As

Publication number Publication date
AU2019256289A1 (en) 2020-11-12
CN112543645A (zh) 2021-03-23
KR20210011923A (ko) 2021-02-02
MX2020010968A (es) 2021-01-08
SG11202010178XA (en) 2020-11-27
US20210230261A1 (en) 2021-07-29
IL278041A (en) 2020-11-30
CA3097123A1 (en) 2019-10-24
WO2019204380A1 (en) 2019-10-24
EP3781199A1 (en) 2021-02-24
JP2021522180A (ja) 2021-08-30

Similar Documents

Publication Publication Date Title
US20210230261A1 (en) Buffered formulations of bevacizumab for use of treating diseases
US20260098085A1 (en) Methods for treating age-related macular degeneration
TWI727279B (zh) 治療眼部疾病之方法
EP3397281B1 (en) Buffered formulations of bevacizumab
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
BR112020022610A2 (pt) proteína de fusão de receptor de vegf de alta concentração que contém formulações
US20220251210A1 (en) Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof
JP7089121B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
KR20260025887A (ko) 익상편을 치료하기 위한 조성물 및 방법
JP7828274B2 (ja) 眼疾患を治療するための方法
JP2013136588A (ja) ＩＬ−１ｒａの凝集を低下させる方法
CN121285391A (zh) 聚唾液酸-聚合物缀合物和纳米颗粒
US20220251188A1 (en) Formulation comprising anti-lag-3 antibody, method for preparing same and use thereof
US20250325666A1 (en) Pharmaceutical compositions containing anti-her2 antibody for subcutaneous administration
Sergeys et al. SRC INHIBITION AS POTENTIAL TREATMENT STRATEGY FOR DIABETIC RETINOPATHY
CN121194795A (zh) 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞
TW202532435A (zh) 治療新生血管性眼疾之方法
HK40114418A (en) Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration
TW202227121A (zh) 以含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）之眼用組成物治療乾眼症
Pece et al. Efficacy and safety of anti-VEGF therapy with intravitreal ranibizumab (LUCENTIS™) for naïve retinal vein occlusion: one-year follow-up

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2876 DE 18-02-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.